Earnings call transcript: Auxly Cannabis Q1 2026 sees record revenue growth

Auxly reported record Q1 2026 net revenue of CAD 39.8 million, up 22% year over year and ahead of the CAD 35.9 million estimate by 10.7%. Gross margin improved to 55% from 48%, adjusted EBITDA rose 65% to CAD 12.3 million, and cash flow from operations more than doubled to CAD 11.3 million. Management reiterated an unchanged 2026 outlook, highlighted strong Back Forty demand, and launched a buyback authorization for up to 4.9% of shares.

Analysis

The key signal is not the revenue beat itself; it is the step-change in cash generation with a relatively fixed debt load. In a small-cap consumer/regulated name, that combination typically compresses financing risk faster than the market re-rates operating quality, which creates a lagged valuation trade-up opportunity. The more important second-order effect is that internal capital allocation now becomes the swing factor: once management can self-fund capex and still buy back stock, the equity starts to behave less like a distressed operator and more like a cash-return story.

The competitive read-through is negative for weaker Canadian LPs. If Auxly is sustaining share in flower/pre-rolls while holding margins, it implies the market is entering a consolidation phase where brand strength and manufacturing efficiency matter more than broad category growth. That should pressure subscale operators with poor product differentiation, because the shelf-space and procurement advantage migrates toward the few names that can combine value, consistency, and innovation without sacrificing economics.

The contrarian issue is that the stock may still be under-owned because investors are anchoring on cannabis-sector stigma rather than free-cash-flow durability. The market is likely underestimating how much optionality a 4.8x EV/EBITDA cash generator has when it starts repurchasing shares and selectively pursuing M&A from a position of strength. The real risk is not near-term execution; it is that cannabis price compression or a regulatory shock can quickly erase the apparent margin floor, so the thesis is strongest over the next 2-4 quarters rather than as a multi-year hold without monitoring.

Key Decisions for Investors

• Long XLY.TO for a 3-6 month trade: risk/reward is attractive if the market starts capitalizing cash flow instead of revenue; downside is capped by balance-sheet improvement, while upside comes from NCIB support and multiple expansion.
• Pair trade: long XLY.TO / short a weaker Canadian LP with inferior margins and leverage for 1-2 quarters; the spread should widen if category consolidation continues and capital markets remain tight.
• Buy XLY.TO on any post-earnings drift or market weakness below the recent close, with a stop if next-quarter commentary shows gross margin slipping below the mid-50s or capex execution stalls.
• Use a covered-call overlay on an existing XLY.TO position over the next 1-2 months; implied upside is likely limited until the buyback or another catalyst forces a re-rate, while downside is cushioned by cash flow.
• Avoid chasing AYURF: management’s discipline on M&A is a negative signal for deal-arb upside and suggests the asset value was not compelling enough versus organic returns.